Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 4, 2013, Pages

  Xia, Yun ^a,b   Luo, Hui ^a   Liu, Jian Ping ^a,b   Gluud, Christian ^b  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PHYLLANTHUS EXTRACT; PLANT EXTRACT; THYMOSIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRUS DNA; DRUG DERIVATIVE;

ALL CAUSE MORTALITY; ARTHRALGIA; CHRONIC HEPATITIS B; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; LEUKOPENIA; LIVER; LIVER CELL CARCINOMA; MORBIDITY; OUTCOME ASSESSMENT; PHYLLANTHUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEROCONVERSION; SLEEP DISORDER; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; BLOOD; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOLOGY; META ANALYSIS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; PHYLLANTHUS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THYMOSIN;

EID: 84886826806     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009004.pub2     Document Type: Review

References (84)

1. Ge X, Song WL, Heng SX, Yang WD. Therapeutic effect observation of phyllanthus tablet for patients with lamivudine resistant hepatitis B. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 2005;15(1):50-2.
2. Huang ZC, Zhu BX, Zheng QJ, Yang SL, Tan B, He JY, et al.A comparative study on phyllanthus compound and lamivudine in the treatment of chronic hepatitis B. Journal of Guangzhou University of Traditional Chinese Medicine 2004;21(3):161--3.
3. Li CQ, Wang XH, Li GQ, Fang HX. Clinical observation of compound phyllanthus for patients with chronic hepatitis B. Journal of New Chinese Medicine 1998;30(6):45-6.
4. Ouyang L. Thymosin and phyllanthus tablets for chronic hepatitis B in 42 cases. Chinese Journal of Traditional and Western Medicine on Liver Disease 1999;9(5):44.
5. Zhu YC. Therapeutic effect observation of compound phyllanthus and thymosin alpha 1 for chronic hepatitis B. Anti Infection Pharmacy 2005;2(4):165-6.
6. Cai XM. Phyllanthus tablets and lamivudine for chronic hepatitis B in 32 cases. Chinese Journal of Integrated Traditional and Western Medicine on Liver Disease 2006;16(6):368-9.
7. Chan HLY, Sung JJY, Fong WF, Chim AML, Yung PP, Hui AY, et al.Double-blinded placebo-controlled study of phyllanthus urinaris for the treatment of chronic hepatitis B. Alimentary Pharmacology and Therapeutics 2003;48(3):339-45.
8. Cheng SL, Yin SS, Liu CY, Zhang JY. Compound phyllanthus tablet and Interferon for children with chronic hepatitis B in 30 cases. Chinese Journal of Integrated Traditional and Western Medicine on Liver Disease 2005;15(1):59.
9. Cui YJ, Gao WJ, Qiao HC. Phyllanthusnirud Linn for patients with chronic hepatitis B virus infection. Chinese Journal of Traditional Chinese Medicine and Pharmacy 1998;13(5):74.
10. Gu HH, Chen QW, Zhou X, Wu WY, Zhao GG. Phyllanthus and vidarabine for chronic hepatitis B in 34 cases. Chinese Journal of Integrated Traditional and Western Medicine on Digestion 2005;13(5):332-3.
11. He LF. Therapeutic effect observation of adefovir dipivoxil and phyllanthus for chronic hepatitis B. Sichuan Medical Journal 2008;29(4):435-6.
12. Huang ZR, Zhong JP, Zhu GL, Chen YD, Wang GQ. Therapeutic effect observation of phyllanthus for patients with chronic hepatitis B. Chinese Journal of Clinical Hepatology 1993;9(2):108-10.
13. Huang L, Zhang FX, Li CQ. Compound phyllanthus and Interferon for chronic hepatitis B. Shanxi Journal of Traditional Chinese Medicine 1999;20(4):146-7.
14. Huang KM. Phyllanthus for patients with chronic hepatitis B in 38 cases. Information of Traditional Chinese Medicine 1999;6:32.
15. Ma FX, Zhang Y. Clinical observation of compound phyllanthus for asymptomatic carriers of hepatitis B. Journal of Shanghai Traditional Chinese Medicine 1993;5:8-9.
16. Qian HQ. Phyllanthus tablet and adefovir dipivoxil tablet for chronic hepatitis B in 42 cases. Chinese Journal of Integrated Traditional and Western Medicine on Liver Disease 2008;18(2):115.
17. Song XA, Ma XL, Liu YM. Therapeutic effect observation of phyllanthus capsule for chronic hepatitis B in 98 cases. Shandong Medical Journal 2007;47(23):97-8.
18. Su BL, Xu PR, Lu J. Therapeutic effect observation of phyllanthus tablet and lamivudine for chronic hepatitis B. Hebei Journal of Chinese Medicine 2004;26(2):146-7.
19. Tian GJ, Feng TB, Tang MZ, Wang XH. Short-term effect of phyllanthus compound and lamivudine in treating chronic hepatitis B: an observation of 30 cases. Journal of Guangzhou University of Traditional Chinese Medicine 2004;21(4):257-9.
20. Wang SH, Xia SL, Zhang Y, Su Z, Wang LJ, Li DT. Clinical study of phyllanthus for patients with chronic hepatitis B. Journal of Infectious Disease Pharmacy 2000;10(2):31-3.
21. Wang WX, Zhou WH, Shen LJ. Phyllanthus and adefovir dipivoxil tablets for chronic hepatitis B in 20 cases. Herald of Medicine 2009;28(1):74-5.
22. Yan J, Liu XQ, Du M, Chen LY. Therapeutic effect observation interferon alpha and phyllanthus capsule for chronic hepatitis B. Journal of Clinical Hepatology 2008;11(1):37-8.
23. Zhang MJ, Dong P, Yong J, Teng J, Li ZX. Therapeutic effect observation of phyllanthus for patients with chronic hepatitis B. Journal of Ningxia Medical College 2006;28(5):451-2.
24. Zhang HF, Zhu SX, Dong Y, Xu ZQ, Chen DW, Jia WZ, et al.The effect and safety assessment of phyllanthus capsule and adefovir dipivoxil tablet for chronic hepatitis B. Shandong Medical Journal 2009;49(28):60-1.
25. Zhong JP, Zhu GL, Huang ZR, Shu ZM, Fei YM, Tang JL, Wang GQ, Chen BC. Therapeutic effect observation of phyllanthus for patients with chronic hepatitis B. Journal of Clinical Hepatology 2000;16(3):186-7.
26. Zhu FM, Zhang JQ, Zhang XZ, Zhang XM. Clinical observation of phyllanthus on hepatitis B viral markers. Chinese Journal of Integrated Traditional Chinese and Western Medicine 1992;2(2):10-1.
27. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. Journal of Hepatology 2003;38(2):215-22.
28. Bagalkotkar G, Sagineedu SR, Saad MS, Stanslas J. Phytochemicals from phyllanthus niruri Linn and their pharmacological properties: a review. Journal of Pharmacy and Pharmacology 2006;58(12):1559-70.
29. Blumberg BS. Hepatitis B virus: search for plant-derived antiviral. In: Tomlinson TR, Akerele D editor(s). Medical Plants - Their Role in Health and Biodiversity. Philadelphia: University of Pennsylvania Press, 1998:7.
30. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
31. Calixto JB, Santos ARS, Filbo VC, Yunes RA. A review of the plants of the genus phyllanthus: their chemistry, pharmacology, and therapeutic potential. Medical Research Review 1998;18(4):225-58.
32. Chang CW, Lin MT, Lee SS, Liu KC, Hsu FL, Lin JY. Differential inhibition of reverse transcriptase and cellular DNA polymerase-alpha activities by Lignans isolated from Chinese herbs, phyllanthus Myrtifolius Moon, and tannins from Lonicera Japonica Thunb and Castanopsis hystrix. Antiviral Research 1995;27(4):367-74.
33. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al.Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New England Journal of Medicine 1997;336(26):1855-9.
34. Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD000100.pub3].
35. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The Guideline of Prevention and Treatment of Chronic Hepatitis B. Chinese Journal of Hepatology 2005;12:1.
36. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. http://ctu.dk/tsa/ (accessed 4 September 2012).
37. DeMets DL. Practical aspects in data monitoring: a brief review. Statistics in Medicine 1987;6(7):753-60.
38. DerSimonian R, Laid N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 3802833].
39. European Association for the Study of the Liver. EASL Clinical Practice Guidellines: Management of chronic hepatitis B. Journal of Hepatology 2009; Vol. 50, issue 2:227-42.
40. Garaci E, Favalli C, Pica F, Sinibaldi Vallebona P, Palamara AT, Matteucci C. Thymosin alpha 1: from bench to bedside. The New York Academy of Sciences 2007;1112:225-34.
41. Gluud C, Brok J, Gong Y, Koretz R. Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology 2007;46:734-42.
42. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2011, Issue 8. Art. No.: LIVER.
43. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opinion on Biological Therapy 2009;9(5):593-608.
44. Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Colloboration, 2009. Available from www.cochrane-handbook.org.
45. Hu M, Chen W. Assessment of total economic burden of chronic hepatitis B-related disease in Beijing and Guangzhou, China. Value in Health 2009;12(3):89-92.
46. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
47. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ (Clinical Research Ed.) 2001;323(7303):42-6.
48. Kathriarachchi H, Hoffmann P, Samuel R, Wurdack KJ, Chase MW. Molecular phylogenetics of phyllanthaceae inferred from five genes. Molecular Phylogenetics and Evolution 2005;36(1):112-34.
49. Khatoon S, Rai V, Rawat AK, Mehrotra S. Comparative pharmacognostic studies of three Phyllanthus species. Journal of Ethnopharmacology 2006;104(1-2):79-86.
50. Kjaergaard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomised trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
51. Lam WY, Leung KT, Law PT, Lee SM, Chan HL, Fung KP, et al.Antiviral effect of phyllanthus nanus ethanolic extract against hepatitis B virus (HBV) by expression microarray analysis. Journal of Cellular Biochemistry 2006;97(4):795-812.
52. Lee CD, Ott M, Thyagarajan SP, Shafritz DA, Burk RD, Gupta S. Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication. European Journal of Clinical Investigation 1996;26(12):1069-76.
53. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004790.pub2].
54. Liaw YF, Leung N, Guan R, Lau GK, Merican I. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. Journal of Gastroenterol Hepatology 2003;18(3):239-45.
55. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver International 2005;25(3):472-89.
56. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatology International 2008;2(3):263-83.
57. Lin L, Lin JW. Advance in research on the thymosin preparation. Chinese Pharmaceutical Affairs 2009;23(7):706-10.
58. Liu Z, Fu X, Zhang N, Zhang G, Liu D. The inhibitory effect of Chinese herb Phyllanthus on hepatitis B virus in vitro. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1997;11(3):282-5.
59. Liu JP, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infections: a systematic review. Journal of Viral Hepatitis 2001;8:358-66.
60. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2009;50(3):661-2.
61. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2].
62. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine 2003;348:808-16.
63. Mathew JL, El Dib R, Mathew PJ, Boxall EH, Brok J. Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure status. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006481.pub2].
64. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
65. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al.Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991;14(3):409-15.
66. Ott M, Thyagarajan SP, Gupta S. Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. European Journal of Clinical Investigation 1997;27(11):908-15.
67. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
68. Royle P, Milne R. Literature searching for randomised controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
69. Saconato H, Atallah ÁN, Souza GM, Parise ER. Thymosin alpha1 for chronic hepatitis B. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD003621].
70. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
71. Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
72. Scaglione SJ, Lok ASF. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012;142(6):1360-8.
73. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
74. Shi G, Xie YF, Liu XY. Estimation of economic burden of hepatitis B. Chinese Primary Health 2004;8:18-9.
75. Sun J, Hou JL. Management of chronic hepatitis B: experience from China. Journal of Viral Hepatitis 2010;17(1):10-7.
76. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual forTrial Sequential Analysis (TSA). http://ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 4 Spetember 2012).
77. Venateswaran PS, Millman I, Blumberg BS. Effects of an extract from phyllanthus niruri on hepatitis B virus and woodchuck hepatitis viruses: in vitro and in vivo studies. Proceedings of the National Academy of Sciences 1987;84(1):274-8.
78. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
79. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
80. WHO 2001. Introduction of hepatitis B vaccine into childhood immunization services. Management guidelines, including information for health workers and parents. www.who.int/vaccines-documents/DocsPDF01/www613.pdf 2001 (accessed 26 October 2010).
81. WHO 2008. Hepatitis B. World Health Organization Fact Sheet 204 (Revised August 2008). http://www.who.int/mediacentre/factsheets/fs204/en/index.html 2008 (accessed 26 October 2010).
82. World Health Organization. Viral hepatitis. Report by the secretariat. http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf (accessed January 2010).
83. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
84. Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD008960.pub2].